InnoCan Pharma Corporation
InnoCan Pharma Corporation, a pharmaceutical technology company, focuses on the development of various drug delivery platforms combining cannabidiol (CBD) with other pharmaceutical ingredients in the United States, Canada, Europe, and internationally. The company operates in two segments: Online Sales and Other Operations. It engages in the research and development of CBD loaded exosomes, as well… Read more
InnoCan Pharma Corporation (INNPF) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: 0.002x
Based on the latest financial reports, InnoCan Pharma Corporation (INNPF) has a cash flow conversion efficiency ratio of 0.002x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($13.84K) by net assets ($6.63 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
InnoCan Pharma Corporation - Cash Flow Conversion Efficiency Trend (2015–2024)
This chart illustrates how InnoCan Pharma Corporation's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
InnoCan Pharma Corporation Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of InnoCan Pharma Corporation ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
ON SEMICONDUCTOR
MU:XS4
|
0.054x |
|
NO GRAVITY GAMES ZY -10
F:8YX
|
N/A |
|
Kmc Properties ASA
OL:KMCP
|
0.500x |
|
FLEXTRONICS INTL - Dusseldorf Stock Exchang
DU:FXI
|
0.064x |
|
TYSON FOODS -A- - Dusseldorf Stock Exchang
DU:TF7A
|
0.044x |
|
Sentoria Group Bhd
KLSE:5213
|
-2.641x |
|
Ralco Agencies Ltd
TA:RLCO
|
0.187x |
|
Panacea Life Sciences Holdings Inc
OTCQB:PLSH
|
-0.388x |
Annual Cash Flow Conversion Efficiency for InnoCan Pharma Corporation (2015–2024)
The table below shows the annual cash flow conversion efficiency of InnoCan Pharma Corporation from 2015 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $7.02 Million | $-1.58 Million | -0.225x | +74.74% |
| 2023-12-31 | $4.39 Million | $-3.90 Million | -0.890x | +8.67% |
| 2022-12-31 | $6.22 Million | $-6.07 Million | -0.975x | -32.48% |
| 2021-12-31 | $9.01 Million | $-6.63 Million | -0.736x | -171.97% |
| 2020-12-31 | $-3.61 Million | $-3.69 Million | 1.022x | +153.20% |
| 2019-12-31 | $1.41 Million | $-2.71 Million | -1.921x | +73.15% |
| 2018-12-31 | $127.00K | $-909.00K | -7.157x | -22690.40% |
| 2017-12-31 | $1.05 Million | $-33.12K | -0.031x | -117.64% |
| 2016-12-31 | $1.33 Million | $237.54K | 0.178x | -7.99% |
| 2015-12-31 | $1.69 Million | $326.68K | 0.193x | -- |